Safety and Maintenance Study of Entocort for Children With Crohn's Disease

January 4, 2022 updated by: Padagis LLC

A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive

A Safety for Maintenance of Entocort EC for children with mild to moderate Crohn's Disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A Multicenter, Open label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive

Study Type

Interventional

Enrollment (Actual)

55

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Nova Scotia
      • Halifax, Nova Scotia, Canada
        • Research Site
    • Ontario
      • London, Ontario, Canada
        • Research Site
  • Germany
      • München, Germany
        • Research Site
      • Nürnberg, Germany
        • Research Site
  • Italy
      • Firenze, Italy
        • Research Site
      • Messina, Italy
        • Research Site
      • Roma, Italy
        • Research Site
  • Poland
      • Kraków, Poland
        • Research Site
      • Rzeszów, Poland
        • Research Site
      • Warszawa, Poland
        • Research Site
      • Wrocław, Poland
        • Research Site
      • Łódź, Poland
        • Research Site
  • United States
    • Georgia
      • Atlanta, Georgia, United States
        • Research Site
    • Illinois
      • Oak Lawn, Illinois, United States
        • Research Site
    • Massachusetts
      • Newton, Massachusetts, United States
        • Research Site
    • Minnesota
      • Saint Paul, Minnesota, United States
        • Research Site
    • New Jersey
      • Mays Landing, New Jersey, United States
        • Research Site
    • New York
      • Buffalo, New York, United States
        • Research Site
    • Texas
      • Houston, Texas, United States
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit.
  • All subjects must weight >= 15 kg at the time of enrollment.
  • Subjects must have been diagnosed and treated for active Crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology and have a PCDAI <= 10

Exclusion Criteria:

  • Subjects who have had any previous intestinal resection proximal to and including the ascending colon.
  • Subjects with evidence of active Crohn's disease (PCDAI > 10) and/or stricturing, prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications.
  • Subjects with morning cortisol level <150 nmol/l (5.4 ug/dl) or DHEA-S below normal range for age and gender (NOTE: Subjects from the induction protocol with abnormal morning cortisol/DHEA-S levels at Visit 4, who otherwise meet the eligibility criteria, may be enrolled if the investigator decides that Entocort 6 mg is an appropriate therapy option.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Entocort
Study Medication
Drug: Entocort
Entocort capsules, taken orally, 6 mg daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Event
Time Frame: 16 weeks
Any kind of adverse event
16 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PCDAI
Time Frame: 12 weeks
Pediatric Crohn's Disease Activity Index. The scale ranges from 0 (no activity) to 100 (high activity)
12 weeks
IMPACT 3
Time Frame: 12 weeks
IMPACT-III - A QUALITY OF LIFE QUESTIONNAIRE FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Padagis LLC

Investigators

  • Study Director: Stefan Eklund, MD, AstraZeneca Pharmaceuticals, Mölndal, Sweden
  • Principal Investigator: Stanley Cohen, MD, Children's Center for Digestive Healthcare, LLC, Atlanta, Georgia, USA

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2011

Primary Completion (Actual)

February 1, 2014

Study Completion (Actual)

February 1, 2014

Study Registration Dates

First Submitted

October 14, 2011

First Submitted That Met QC Criteria

October 17, 2011

First Posted (Estimate)

October 18, 2011

Study Record Updates

Last Update Posted (Actual)

January 6, 2022

Last Update Submitted That Met QC Criteria

January 4, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • D9422C00002

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Crohn's Disease

Clinical Trials on Entocort

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe